Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes
Webcast
1 AMA PRA Category 1 Credit™ OVERVIEW
Updates in Retinal Disease Care: Keeping an Eye on Emerging Anti-VEGF Therapies & Improved Outcomes is organized by Rockpointe Corporation.
Release Date: Dec 20, 2022
Expiration Date: Dec 20, 2023
Description:
The prevalence of retinal diseases such as age-related macular degeneration and diabetic macular edema is projected to rise dramatically in the coming decades with an aging population and the increasing prevalence of diabetes. The availability of anti-vascular endothelial growth factor (VEGF) therapies has significantly improved outcomes for patients with retinal disease for over a decade. However, the need for frequent intravitreal injections required to obtain the best possible patient outcomes with anti-VEGF therapies has added to the patient burden associated with retinal disease management. This also led many clinicians and patients to opt for as-needed dosing intervals guided by optical coherence tomography results, which may be more expedient for patients but has also been associated with the worsening of retinal disease and vision loss. Thus, an unmet need persists for more efficacious therapies with increased duration of response to minimize the number of injections required for the many patients with retinal disease. There are newly available therapeutic options, such as the port delivery system with ranibizumab and the dual anti-VEGF, anti-Ang-2 binding farcical; along with several emerging, novel therapies including sustained-release anti-VEGF formulations, combination anti-VEGFs, and gene therapy
Educational Objectives:
At the conclusion of this education, participants should be able to:
- Assess risks/benefits of fixed, frequent dosing intervals versus individualized dosing intervals for anti-VEGF therapies
- Select anti-VEGF dosing intervals that provide the best potential outcomes for patients with retinal disease
- Assess the safety and efficacy of recently approved and emerging retinal disease therapies
ACCREDITATION & CREDITS
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN DESIGNATION CREDIT STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABO MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement for the American Board of Opthalmology's Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
TARGET AUDIENCE
PhysicianCliniciansOphthalmologistSPECIALITIES
Ophthalmology
Quick Links